Rallybio Q3 net loss $10.2M ($0.37/share); cash $187M; pipeline on track

Rallybio Corp

2022-Q3 EPS reported -$1.44

Net loss $10.2M vs $7.2M in Q3 2020; R&D $5.0M flat; G&A $5.0M up from $1.6M.
Cash and equivalents $187.0M, including $83M net from August 2021 IPO.
Initiated FNAIT natural history study to support RLYB212 registration trial design.
On-track to report additional Phase 1/2 RLYB211 data in Q4 2021.
Phase 1 studies for RLYB212 and RLYB116 expected to start in Q1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.